EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Development and Validation of a Simulation Model for Treatment to Maintain Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Zachary S Wallace iD, John H Stone iD, Xiaoqing Fu, Peter A Merkel iD, Eli M Miloslavsky iD, Yuqing Zhang iD, Hyon K Choi iD, Emily P Hyle

Arthritis Care & Research · 2023

DOI: 10.1002/acr.25088 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Arthritis Care & Research, 2023. Verfasst von Zachary S Wallace und 7 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Antibodies, Antineutrophil Cytoplasmic, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Fixed and tailored rituximab retreatment strategies to maintain remission in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) are associated with tradeoffs. The current study was undertaken to develop a simulation model (AAV‐Sim) to project clinical outcomes with these strategies.

Methods

We developed the AAV‐Sim, a microsimulation model of clinical events among individuals with AAV initiating treatment to maintain remission. Individuals transition between health states of remission or relapse and are at risk for severe infection, end‐stage renal disease, or death. We estimated transition rates from published literature, stratified by individual‐level characteristics. We performed validation using the mean average percent error (MAPE) and the coefficient of variation of root mean square error (CV‐RMSE). In internal validation, we compared model‐projected outcomes over 28 months with outcomes observed in the Rituximab versus Azathioprine in ANCA‐Associated Vasculitis 2 (MAINRITSAN2) trial, which compared fixed versus tailored retreatment. In external validation, we compared outcomes with fixed rituximab retreatment from the AAV‐Sim to outcomes from the MAINRITSAN1 trial and an observational study.

Results

The AAV‐Sim projected outcomes similar to those in the MAINRITSAN2 trial, including minor (AAV‐Sim 6.0% fixed versus 7.3% tailored; MAINRITSAN2 6.2% versus 8.6%; MAPE 3% and 15%) and major relapse (AAV‐Sim 3.5% versus 5.5%; MAINRITSAN2 3.7% versus 7.4%; MAPE 5% and 26%), severe infection (AAV‐Sim 19.4% versus 11.1%; MAINRITSAN2 19.8% versus 10.2%; MAPE 2% and 9%), and relapse‐free survival (AAV‐Sim 84.8% versus 82.3%; MAINRITSAN2 86% versus 84%; CV‐RMSE 2.3% and 2.5%). Similar performance was observed in external validation.

Conclusion

The AAV‐Sim projected a range of clinical outcomes for different treatment approaches that were validated against published data. The AAV‐Sim has the potential to inform management guidelines and research priorities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Antineutrophil CytoplasmicAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisHumansRituximabRemission InductionAzathioprine

Substanzen

RituximabAntibodies, Antineutrophil CytoplasmicAzathioprine

Autor:innen und Institutionen

  • Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Massachusetts General Hospital, Boston.
  • University of Pennsylvania, Philadelphia.

ORCID-Profile: Zachary S Wallace, John H Stone, Peter A Merkel, Eli M Miloslavsky, Yuqing Zhang, Hyon K Choi

Förderung

  • NIAMS NIH HHS
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • Rheumatology Research Foundation

Zitieren

APA

Wallace, Z. S., Stone, J. H., Fu, X., Merkel, P. A., Miloslavsky, E. M., Zhang, Y., Choi, H. K., & Hyle, E. P. (2023). Development and Validation of a Simulation Model for Treatment to Maintain Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis Care & Research. https://doi.org/10.1002/acr.25088

Vancouver

Wallace ZS, Stone JH, Fu X, Merkel PA, Miloslavsky EM, Zhang Y, et al. Development and Validation of a Simulation Model for Treatment to Maintain Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis Care & Research. 2023. doi:10.1002/acr.25088

BibTeX
@article{Wallace2023,
  author = {Wallace, Zachary S and Stone, John H and Fu, Xiaoqing and Merkel, Peter A and Miloslavsky, Eli M and Zhang, Yuqing and Choi, Hyon K and Hyle, Emily P},
  title = {Development and Validation of a Simulation Model for Treatment to Maintain Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis},
  journal = {Arthritis Care & Research},
  year = {2023},
  doi = {10.1002/acr.25088}
}
Kostenlos starten →